SCHEMBL6870069

SCHEMBL6870069

OC(C#Cc1ccsc1)c1ccsc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.42
GRM5 P41594 4/20 0.40
ALOX5 P09917 1/20 0.33
IDO1 P14902 2/20 0.33
TDO2 P48775 2/20 0.33
IKBKB O14920 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CACNA2D1 P54289 1/20 0.30
CACNB2 Q08289 1/20 0.30
CACNA1C Q13936 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
HCRTR1 O43613 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799330 0.86 IDO1 (0.40) CYP2A6GRM5IDO1TDO2CACNA2D1
SCHEMBL17604705 0.76 ALOX5 (0.36) ALOX5IDO1TDO2CACNA2D1CACNB2
SCHEMBL6958800 0.72
SCHEMBL17032815 0.72 GRM5 (0.44) CYP2A6GRM5ALOX5IKBKBTDP1
SCHEMBL9299297 0.71 ALOX5 (0.37) GRM5ALOX5IKBKB
SCHEMBL20217413 0.69
SCHEMBL31556324 0.68 CYP3A4 (0.44) CYP2A6ALOX5IDO1TDO2L3MBTL1
Bromide SCHEMBL23883200 0.66 CYP2A6 (0.41) CYP2A6GRM5IDO1TDO2TDP1
SCHEMBL5101400 0.65
SCHEMBL1300584 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438309-A1 QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS UCB, S.A. (BE) 2004-07-21 EP claimed
WO-2003033495-A1 QUINUCLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS M2 AND/OR M3 MUSCARINIC RECEPTOR INHIBITORS UCB, S.A. (BE) 2003-04-24 WO claimed